Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
ATAI Forecast Markets
AtaiBeckley Inc.
7
Active Markets
35%
Avg Probability
All Markets
7 markets
Will ATAI dose the first patient in both BPL-003 Phase 3 pivotal trials by 2026-09-30?
60%
Likely Yes
88% agreement
Sep 30, 2026
IG: 0.72
Will ATAI price a follow-on equity offering of at least $200M at a discount of less than 20% to prior-close by 2026-12-31?
35%
Likely No
88% agreement
Dec 31, 2026
IG: 0.64
Will ATAI's stock price close below $3.00 on any trading day in 2026?
43%
Likely No
86% agreement
Dec 31, 2026
IG: 0.56
Will ATAI disclose an unplanned DSMB safety communication for BPL-003 Phase 3 trials by 2026-12-31?
9%
Likely No
92% agreement
Dec 31, 2026
IG: 0.48
Will ATAI's CEO or CFO disclose open-market net selling of more than $500K via Form 4 in 2026?
38%
Likely No
88% agreement
Dec 31, 2026
IG: 0.40
Will a competing psychedelic Phase 2b or Phase 3 TRD/MDD program (Cybin CYB003, MindMed MM120, or COMPASS COMP360) report a statistically significant primary endpoint hit by 2026-12-31?
40%
Likely No
89% agreement
Dec 31, 2026
IG: 0.40
Will ATAI disclose at least 50% enrollment in one or both BPL-003 Phase 3 pivotal trials by 2026-12-31?
22%
Likely No
90% agreement
Dec 31, 2026
IG: 0.36
Resolution Timeline
Sep 30, 2026
Will ATAI dose the first patient in both BPL-003 Phase 3 pivotal trials by 2026-09-30?Prediction: 60%
Dec 31, 2026
Will ATAI disclose an unplanned DSMB safety communication for BPL-003 Phase 3 trials by 2026-12-31?Prediction: 9%
Dec 31, 2026
Will ATAI's CEO or CFO disclose open-market net selling of more than $500K via Form 4 in 2026?Prediction: 38%
Dec 31, 2026
Will ATAI disclose at least 50% enrollment in one or both BPL-003 Phase 3 pivotal trials by 2026-12-31?Prediction: 22%